Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04674969 · ClinicalTrials.gov registry record
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
A clinical trial of Peripheral Vascular Diseases, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 20
- Study locations
NCT04674969: Recruiting study of Peripheral Vascular Diseases, sponsored by Boston Scientific Corporation.
NCT04674969 is a study of Peripheral Vascular Diseases that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 5,000 participants, above the 234-participant average among 19 other Peripheral Vascular Diseases trials with a reported enrollment target (2037% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04674969, a study of Peripheral Vascular Diseases, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Primary Outcome
Rate of MAEs, which include Target Lesion Revascularizations, Major Target Limb Amputations, and Deaths. No pre-specified endpoints or formal tests of hypotheses are proposed. Analyses will be performed for exploratory purposes.
Conditions Studied
Interventions
- DEVICE Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.
Study Locations (20)
California
- PIH Health Good Samaritan Hospital - Los Angeles
- Cedars - Sinai Medical Center - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- Sutter Medical Center, Sacramento - Sacramento
- Adventist Health St Helena Hospital - St. Helena
Louisiana
- CIS Clinical Research Corporation - Houma
- Ochsner Clinic Foundation - Kenner
- Cardiovascular Institute of the South - Lafayette
Florida
- Palm Beach Heart & Vascular, LLC - Boynton Beach
- Tallahassee Memorial Hospital - Tallahassee
Georgia
- Emory University Hospital - Atlanta
- South Georgia Medical Center - Valdosta
Illinois
- Rush University - Chicago
- St. John's Hospital/ Prairie Education and Research Cooperative - Springfield
Indiana
- St. Joseph Hospital/Dupont Hospital - Fort Wayne
- Ascension St. Vincent's Hospital - Indianapolis
Arkansas
- St. Bernard's Medical Center - Jonesboro
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2021-03-29 |
| Est. Completion | 2028-01 |
What NCT04674969 shows while recruiting
NCT04674969 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 234-participant average among 19 other Peripheral Vascular Diseases trials with a reported enrollment target (2037% higher).
The record links to 1 condition, with Peripheral Vascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. is the first listed.
NCT04674969 names 20 study sites across 10 states, led by California, Louisiana, Florida.
Frequently Asked Questions
What is clinical trial NCT04674969 about?
NCT04674969 is a clinical study titled "Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature". The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices f...
What is the current status of trial NCT04674969?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2021-03-29. Estimated completion is 2028-01.
What conditions does trial NCT04674969 study?
This clinical trial studies the following conditions: Peripheral Vascular Diseases.
What interventions are being tested in trial NCT04674969?
The interventions under investigation include: Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. (DEVICE).
Who is sponsoring clinical trial NCT04674969?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04674969 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Vascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04674969's enrollment target sits among peer trials
5,000 1st of 19 higher than 19 of 19 other Peripheral Vascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Vascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
RECRUITING · Phase 1
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
-
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease
RECRUITING · Early Phase 1
-
MRI Guided Management of Occlusive Peripheral Arterial Disease
RECRUITING
-
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 2
RECRUITING · NA
-
Fisetin to Reduce Senescence and Mobility Impairment in PAD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI